
| Pair Name | Pterostilbene, Vorinostat | ||
| Phytochemical Name | Pterostilbene (PubChem CID: 5281727 ) | ||
| Anticancer drug Name | Vorinostat (PubChem CID: 5311 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Pterostilbene, Vorinostat | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | HIF1A | hsa3091 |
| Down-regulation | Expression | IL1B | hsa3553 | |
| Down-regulation | Expression | MTA1 | hsa9112 | |
| Down-regulation | Expression | VEGFA | hsa7422 | |
| In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
| In Vivo Model | Female C57BL/6J mouse homozygous with "floxed" allele of Pten gene were used in this study. | |||
| Result | Our study provides preclinical evidence that Pter/SAHA combination treatment inhibits MTA1/HIF-1α tumor-promoting signaling in PCa. The beneficial outcome of combinatorial strategy using a natural agent and an approved drug for higher efficacy and less toxicity supports further development of MTA1-targeted therapies in PCa. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017 Nov;6(11):2673-2685. doi: 10.1002/cam4.1209. | Click |